#CMMB

3 months ago

#CMMB Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/CMMB/chemomab-thera...

0 0 0 0

@smcapstrategist.bsky.social

4 months ago

#CMMB Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

www.stocktitan.net/news/CMMB/chemomab-annou...

0 0 0 0

Small Cap Strategist

6 months ago

Trade Alerts, Thursday September 11, 2025 – Crystal Equity Research

Small-cap stocks registering bullish MACD crossover signals, Thu Sept 11th - #VERO #SANA #RELL #AZTA #BWEN #CMMB #DERM #FLL #IMUX #LVO #MBIO #UDMY #TRUG #PDY #NVTS #YRD #UTL #LBRT - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

6 months ago

BREAKING NEWS: ( NASDAQ: #CMMB ) Morning Market Surge: Biotech Bulls Lead Charge with FDA Wins and Breakthrough Trial Data

0 0 0 0

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update Chemomab Therapeutics (Nasdaq: CMMB) reported Q2 2025 financial results and provided updates on its lead drug candidate nebokitug for Primary Sclerosing Cholangitis (PSC). The company is preparing for Phase 3 trials while pursuing strategic partnerships to optimize development resources. Key financial metrics include cash position of $9.5 million as of June 30, 2025, with runway through Q2 2026.Notable developments include FDA alignment on CMC standards and toxicology testing requirements, new patent issuances in China and Russia, and multiple presentations of Phase 2 SPRING trial data at major scientific meetings. The company also announced plans to implement an ADS ratio change from 1:20 to 1:80 effective August 26, 2025, essentially functioning as a 1:4 reverse split for ADS holders.

7 months ago

#CMMB Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/CMMB/chemomab-thera...

0 0 0 0

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25 Chemomab Therapeutics (Nasdaq: CMMB) presented positive Phase 2 SPRING trial data for nebokitug (CM-101) in primary sclerosing cholangitis (PSC) at BSG Live'25. The data was presented by Principal Investigator Dr. Douglas Thorburn at the British Society for Gastroenterology annual meeting in Glasgow.The trial demonstrated that nebokitug was well-tolerated over 48 weeks of treatment, with a safety profile comparable to placebo during the initial 15-week double-blind portion. In patients with moderate to advanced disease, the drug showed dose-dependent anti-inflammatory, anti-fibrotic, and anti-cholestatic effects.The open-label extension portion, lasting up to an additional 33 weeks, revealed sustained improvement in fibrosis markers and other PSC-related parameters. These positive results support advancement to Phase 3 trials, potentially positioning nebokitug as the first approved therapy for PSC.

8 months ago

#CMMB Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25

www.stocktitan.net/news/CMMB/chemomab-annou...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

9 months ago

Woman clutching her abdomen with a highlighted illustration of the liver, symbolizing liver-related health issues, representing Chemomab Therapeutics.

#CMMB dips 8% despite FDA feedback clearing key hurdles for Phase 3 of nebokitug in primary sclerosing cholangitis. Regulatory path is now streamlined, and partnering discussions are underway.
#ChemomabTx
prismmarketview.com/chemomab-adv...

0 0 0 0

FDA Backs Chemomab's Nebokitug Phase 3 Plans: Major Regulatory Win for PSC Treatment FDA endorses two key development milestones for Chemomab's PSC drug candidate. Strategic partnership discussions advance as Phase 3 preparations gain momentum. Learn more.

9 months ago

#CMMB Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

www.stocktitan.net/news/CMMB/chemomab-repor...

0 0 0 0

Breakthrough PSC Treatment: Chemomab Drug Shows Promising Results in 48-Week Trial as FDA Fast-Tracks Approval Path New clinical data reveals nebokitug's success in treating PSC liver disease. FDA confirms streamlined approval pathway for potential first-ever PSC treatment. See trial results.

10 months ago

#CMMB Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/CMMB/chemomab-thera...

0 0 0 0

Breakthrough in PSC Treatment: New Drug Shows Significant Disease-Modifying Potential in Phase 2 Trial Chemomab's nebokitug demonstrates safety and efficacy in 48-week PSC trial, improving multiple disease markers. First potential FDA-approved therapy advances to Phase 3. Learn more.

10 months ago

#CMMB Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

www.stocktitan.net/news/CMMB/chemomab-annou...

0 0 0 0

Breakthrough Phase 2 Data: New Drug Shows Promising Results for Rare Liver Disease PSC Treatment New clinical data reveals dose-dependent improvements across 3,000 protein markers in PSC patients. See comprehensive Phase 2 SPRING trial results.

10 months ago

#CMMB Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases

www.stocktitan.net/news/CMMB/chemomab-repor...

0 0 0 0

Chemomab Bolsters Medical Team as Revolutionary PSC Drug Advances Toward FDA Experienced CMO returns as Chemomab advances first potential FDA-approved PSC treatment. Key appointments follow successful Phase 2 trial completion.

11 months ago

#CMMB Chemomab Announces New Medical and Clinical Appointments

www.stocktitan.net/news/CMMB/chemomab-annou...

0 0 0 0

Game-Changing PSC Treatment Cuts Disease Progression by 80% in Latest Clinical Data Novel PSC therapy demonstrates sustained liver improvements over 48 weeks with 90% patient retention. Phase 3 trial upcoming with optimized dosing. Full analysis inside.

11 months ago

#CMMB Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

www.stocktitan.net/news/CMMB/chemomab-repor...

0 0 0 0

Can This Novel Antibody Transform Systemic Sclerosis Treatment? New Clinical Evidence Emerges New data validates nebokitug's dual anti-inflammatory and anti-fibrotic mechanism in SSc, with strong biomarker improvements and correlation to disease outcomes.

1 year ago

#CMMB New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis

www.stocktitan.net/news/CMMB/new-data-prese...

0 0 0 0

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update ─ Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC) ─ ─ Achieved Alignment with FDA on Clear and Efficient Pathway to Potential Regulatory Approval for the Treatment of PSC with No Liver Biopsies or

1 year ago

#CMMB Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/CMMB/chemomab-thera...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Wed Feb 19th - #WOOF #XOS #CHCT #DEC #FVRR #JELD #MBC #UIC #ALZN #BMBL #CMMB #LNKB #NEXN #PERI #SBLK #TCMD #VACH - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

Charts of the Day - small-cap stocks forming bearish harami candlestick signal, Tue Jan 7th - #CMCM #CMMB - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

1 year ago

#CMMB Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/CMMB/chemomab-thera...

0 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #CMMB ) Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting 2024

#StockMarket #News

1 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #CMMB ) Chemomab Therapeutics to Present at September 2024 Investor Conferences

#StockMarket #News

1 0 0 0